Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:30:32 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



Q:ELEV - ELEVATION ONCOLOGY INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ELEV - Q0.23.53·3.710.23.61173.15561,2813.59  3.67  3.505.89  0.36316:00:02May 0715 min RT 2¢

Recent Trades - Last 10 of 1281
Time ETExPriceChangeVolume
16:00:02Q3.595-0.01541
16:00:01Q3.61 67
16:00:01Q3.61 25
16:00:01Q3.61 1,206
16:00:01Q3.61 438
16:00:01Q3.61 457
16:00:01Q3.61 1
16:00:01Q3.61 2
16:00:01Q3.61 564
16:00:01Q3.61 100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-07 07:30U:ELEVNews ReleaseElevation Oncology to Present at the Citizens JMP Life Sciences Conference
2024-05-02 07:30U:ELEVNews ReleaseElevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
2024-04-08 16:30U:ELEVNews ReleaseElevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
2024-03-06 07:30U:ELEVNews ReleaseElevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
2024-03-05 16:50U:ELEVNews ReleaseElevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
2024-03-04 07:30U:ELEVNews ReleaseElevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors
2024-02-28 07:30U:ELEVNews ReleaseElevation Oncology to Participate in Upcoming Investor Conferences
2024-02-22 07:30U:ELEVNews ReleaseElevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
2024-01-22 07:30U:ELEVNews ReleaseElevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors
2024-01-09 10:25U:ELEVNews ReleaseGlobal Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
2024-01-05 07:30U:ELEVNews ReleaseElevation Oncology Announces Program Updates and Upcoming 2024 Milestones
2023-11-22 07:30U:ELEVNews ReleaseElevation Oncology to Present at the Piper Sandler 35th Annual Healthcare Conference
2023-11-02 07:30U:ELEVNews ReleaseElevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements
2023-09-05 07:30U:ELEVNews ReleaseElevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-16 07:30U:ELEVNews ReleaseElevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021
2023-08-03 07:30U:ELEVNews ReleaseElevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements
2023-07-13 08:00U:ELEVNews ReleaseElevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer
2023-06-08 22:41U:ELEVNews ReleaseElevation Oncology Announces Pricing of $50 Million Public Offering
2023-06-08 16:01U:ELEVNews ReleaseElevation Oncology Announces Launch of Proposed Public Offering
2023-06-03 09:00U:ELEVNews ReleaseElevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023